Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261457239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 28.05.2026. Verfasst von Jing Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China. Hauptthemen laut MEDLINE: Venous Thromboembolism, Mendelian Randomization Analysis, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation of Hebei Provincial Department of Health.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used antidiabetic agents with established cardiorenal benefits, yet their genetic causal association with venous thromboembolism (VTE) remains uncertain.
Methods
We employed a multifaceted approach to investigate the causal relationship between SGLT2 inhibition and VTE, as well as deep vein thrombosis (DVT) and pulmonary embolism (PE). Drug-target Mendelian randomization (MR) and summary-data-based MR (SMR) analyses were conducted using genetic variants proxying SGLT2 inhibition, derived from SLC5A2 expression quantitative trait loci and glycemic traits. Positive control analyses confirmed validity using type 2 diabetes outcomes. Meta-analyses were performed across multiple independent genome-wide association study datasets. Complementary pharmacovigilance analysis was conducted using the FDA Adverse Event Reporting System (FAERS) to assess disproportionality of SGLT2 inhibitor-related VTE reports.
Results
Genetically proxied SGLT2 inhibition was significantly associated with reduced risk of type 2 diabetes (P < 0.05), validating its robustness. Most MR analyses showed no consistent causal association with VTE, DVT, or PE across datasets, and meta-analyses yielded non-significant pooled estimates (all P > 0.05). SMR analyses revealed no association between SLC5A2 expression and VTE-related outcomes (all P_SMR > 0.05). FAERS disproportionality analysis also identified no safety signals for PE (reporting odds ratio [ROR] = 0.51; 95% CI: 0.42–0.64) or DVT (ROR = 0.54; 95% CI: 0.45–0.64).
Conclusions
This integrative study provides consistent evidence that SGLT2 inhibition is not causally associated with VTE, DVT, or PE, supporting its thrombotic safety. However, generalizability to non-European populations requires future validation in diverse cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Graduate School, Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
- Department of Cardiology, Anzhen Hospital Affiliated to Capital Medical University, Beijing, People's Republic of China.
- Department of Immuno-Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
ORCID-Profile: Zhenli Li
Förderung
- Foundation of Hebei Provincial Department of Health
Zitieren
APA
Liu, J., Ma, Z., Liu, P., Yao, T., He, J., Wang, T., Li, M., Liu, S., Ma, J., & Li, Z. (2026). Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261457239
Vancouver
Liu J, Ma Z, Liu P, Yao T, He J, Wang T, et al. Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261457239
BibTeX
@article{Liu2026,
author = {Liu, Jing and Ma, Zipei and Liu, Piaoran and Yao, Tiezhu and He, Jing and Wang, Tenghui and Li, Mengjia and Liu, Sihan and Ma, Jingtao and Li, Zhenli},
title = {Explore the Causal Effect of SGLT2 Inhibition on Venous Thromboembolism Events: A Drug-Target Mendelian Randomization Study With Pharmacovigilance Analysis},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261457239}
}
EUVIMED